444 related articles for article (PubMed ID: 31411985)
1. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Chiang CL; So TH; Lam TC; Choi HCW
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):108-115. PubMed ID: 31273290
[TBL] [Abstract][Full Text] [Related]
5. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Sung WWY; Choi HCW; Luk PHY; So TH
Front Oncol; 2021; 11():627083. PubMed ID: 33718198
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Yoo M; Nelson RE; Haaland B; Dougherty M; Cutshall ZA; Kohli R; Beckstead R; Kohli M
J Natl Cancer Inst; 2023 Nov; 115(11):1374-1382. PubMed ID: 37436697
[TBL] [Abstract][Full Text] [Related]
9. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Barbier MC; Tomonaga Y; Menges D; Yebyo HG; Haile SR; Puhan MA; Schwenkglenks M
PLoS One; 2022; 17(11):e0277282. PubMed ID: 36327294
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Parikh NR; Chang EM; Nickols NG; Rettig MB; Raldow AC; Steinberg ML; Koontz BF; Vapiwala N; Deville C; Feng FY; Spratt DE; Reiter RE; Phillips R; Ost P; Tran PT; Kishan AU
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):917-926. PubMed ID: 32544574
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
[TBL] [Abstract][Full Text] [Related]
16. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
[TBL] [Abstract][Full Text] [Related]
17. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
18. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H; Matsumoto R; Fujimoto K; Mizokami A; Uemura H; Kamoto T; Kawakami S; Nakamura K; Maekawa S; Shibayama K; Watanabe A; Ito M; Tajima Y; Matsuyama H; Uemura H
Eur Urol Oncol; 2024 Jun; 7(3):625-632. PubMed ID: 38296736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
